Cooper Net Income/Loss 2010-2025 | COO
Cooper annual/quarterly net income/loss history and growth rate from 2010 to 2025. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Cooper net income/loss for the quarter ending January 31, 2025 was $0.104B, a 28.45% increase year-over-year.
- Cooper net income/loss for the twelve months ending January 31, 2025 was $0.942B, a 32.7% increase year-over-year.
- Cooper annual net income/loss for 2024 was $0.392B, a 33.34% increase from 2023.
- Cooper annual net income/loss for 2023 was $0.294B, a 23.74% decline from 2022.
- Cooper annual net income/loss for 2022 was $0.386B, a 86.9% decline from 2021.
Cooper Annual Net Income/Loss
(Millions of US $) |
| 2024 |
$392 |
| 2023 |
$294 |
| 2022 |
$386 |
| 2021 |
$2,945 |
| 2020 |
$238 |
| 2019 |
$467 |
| 2018 |
$140 |
| 2017 |
$373 |
| 2016 |
$275 |
| 2015 |
$205 |
| 2014 |
$272 |
| 2013 |
$297 |
| 2012 |
$249 |
| 2011 |
$175 |
| 2010 |
$113 |
| 2009 |
$101 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$16.582B |
$3.895B |
|
The Cooper Companies Inc, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision and CooperSurgical. CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company's products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness.?CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians.
|
